At 17.2x earnings and 15.7x forward earnings, CLX trades like a stable defensive compounder, yet the underlying metrics tell a far more conflicted story. A PEG of 2.1 implies growth does not justify the multiple, especially with next year EPS estimated at $6.14 versus current EPS of 12.1, signaling compression rather than acceleration. The Altman Z-Score of 3.1 suggests no imminent balance sheet distress, but it is not fortress-grade either, and the Current Ratio of 0.7 signals tight liquidity. This is not a screaming bargain; it is a quality franchise priced as stable while fundamental inconsistencies and balance sheet constraints suggest limited margin of safety.